Protagonist Therapeutics (PTGX) Capital Expenditures (2015 - 2026)

Protagonist Therapeutics has disclosed Capital Expenditures across 12 years of filings, most recently posting $215000.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $215000.0, up 551.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 million (up 31.94% YoY), and the FY2025 annual result was $1.6 million, up 17.34% from the prior year.
• Capital Expenditures came in at $215000.0 for Q1 2026 at Protagonist Therapeutics, down from $1.6 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.6 million in Q4 2025 to a low of -$1.3 million in Q3 2025.
• The 5-year median for Capital Expenditures is $176000.0 (2023), against an average of $268470.6.
• Across the five-year window, Capital Expenditures jumped 5321.05% in 2024 and tumbled 2800.0% in 2025, its largest moves.
• Protagonist Therapeutics' Capital Expenditures stood at $70000.0 in 2022, then plunged by 72.86% to $19000.0 in 2023, then surged by 5321.05% to $1.0 million in 2024, then soared by 53.59% to $1.6 million in 2025, then slumped by 86.41% to $215000.0 in 2026.
• The last three Capital Expenditures figures came in at $215000.0 (Q1 2026), $1.6 million (Q4 2025), and -$1.3 million (Q3 2025), per Business Quant data.